General Information of Drug (ID: DMUPS48)

Drug Name
HMS3229G13 Drug Info
Synonyms JAK3 Inhibitor VI; CHEMBL2397013; 856436-16-3; GTPL5995; CCG-206764; RT-013395; (3Z)-5-(pyridin-3-yl)-3-(1H-pyrrol-2-ylmethylidene)-2,3-dihydro-1H-indol-2-one
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
16760524
CAS Number
CAS 856436-16-3
TTD Drug ID
DMUPS48

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
DNL151 DMZT89C Parkinson disease 8A00.0 Phase 1 [3]
DNL201 DMFEORD Parkinson disease 8A00.0 Phase 1 [3]
BIIB094 DMLUO5K Parkinson disease 8A00.0 Phase 1 [4]
Pyrrolo-pyridine derivative 2 DMVNY5I N. A. N. A. Patented [5]
Bidentate ligands of Markush derivative 2 DM2QNMC N. A. N. A. Patented [5]
Oxindole derivative 3 DM0ENF3 N. A. N. A. Patented [5]
Aminopyridine derivative 3 DMSLJE8 N. A. N. A. Patented [5]
Fused thiophene derivative 1 DMV7IX4 N. A. N. A. Patented [5]
Oxindole derivative 4 DM3U58I N. A. N. A. Patented [5]
Bidentate ligands of Markush derivative 1 DMB08D3 N. A. N. A. Patented [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leucine-rich repeat kinase 2 (LRRK2) TTK0FEA LRRK2_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5995).
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2059).
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of Ionis
5 Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.